Table 2.
Study schedule of assessments
| Study period | ||||
| Enrolment | Allocation | Intervention | Follow-up | |
| Time point | −3~0 days | 0 | 7~14 days | 1, 3 and 6 months |
| ENROLMENT: | X | |||
| Eligibility screen | X | |||
| Informed consent | X | |||
| Allocation | X | |||
| INTERVENTIONS: | ||||
| XST treatment | X | |||
| Placebo treatment | X | |||
| ASSESSMENTS: | ||||
| MACE | X | X | ||
| CK-MB | X | X | ||
| cTnT | X | X | ||
| cTnI | X | X | ||
| hsTnI | X | X | ||
| Adverse events | X | X | ||
CK-MB, creatine kinase MB; cTnI, cardiac troponin I; cTnT, cardiac troponin T; hsTnI, high-sensitivity troponin I; MACE, major adverse cardiac events; UA, unstable angina; XST, Xueshuantong injection.